NeuroSearch A/S' 2009 announcement will be on the agenda of a Board meeting
scheduled for 10 March 2010 and will be released immediately hereafter.

On the same day, a teleconference will be held at 3 pm Copenhagen time (2 pm
London time, 9 am New York time), in which Flemming Pedersen, CEO, Anita
Milland, Vice President, CFO and Hanne Leth Hillman, Vice President, Director
of Investor & Capital Market Relations, will present the 2009 announcement and
answer questions. The telephone conference will be conducted in English and the
telephone number is UK: +44 207 509 5139, US: +1 718 354 1226, International
+44 207 509 5139. The corresponding PowerPoint presentation will be available
via www.neurosearch.com prior to the teleconference.

Contact person:
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4460 8212 or +45 4017 5103


About NeuroSearch - Company profile
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ
OMX Copenhagen A/S. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform, focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Janssen Pharmaceutica, Eli Lilly and Company and
GlaxoSmithKline (GSK), and a license collaboration with Abbott. The drug
pipeline comprises eight clinical (Phase I-III) development programmes:
Huntexil® (pridopidine) for Huntington's disease (Phase III), tesofensine for
obesity (ready for Phase III), ABT-894 for ADHD (Phase II) in partnership with
Abbott, ACR343 for schizophrenia (ready for Phase II), ACR325 to treat
dyskinesias in Parkinson's disease (Phase Ib), ABT-560 for the treatment of
cognitive dysfunctions (Phase I) in collaboration with Abbott, NSD-788 for
anxiety/depression (Phase I) and NSD-721 for social anxiety disorder (Phase I)
in partnership with GSK. In addition, NeuroSearch has a broad portfolio of
preclinical drug candidates and holds equity interests in several biotech
companies.